Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study
<h4>Objective</h4> We evaluated the clinical characteristics of metabolic dysfunction-associated fatty liver disease (MAFLD) to evaluate the usefulness of the MAFLD diagnostic criteria in a resident health survey. <h4>Methods</h4> In 1056 participants of a health survey, we c...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683607/?tool=EBI |
| _version_ | 1798016122603175936 |
|---|---|
| author | Tetsuyuki Tateda Chikara Iino Takafumi Sasada Satoshi Sato Go Igarashi Shogo Kawaguchi Kenichiro Mikami Tetsu Endo Kaori Sawada Tatsuya Mikami Shinsaku Fukuda Shigeyuki Nakaji Hirotake Sakuraba |
| author_facet | Tetsuyuki Tateda Chikara Iino Takafumi Sasada Satoshi Sato Go Igarashi Shogo Kawaguchi Kenichiro Mikami Tetsu Endo Kaori Sawada Tatsuya Mikami Shinsaku Fukuda Shigeyuki Nakaji Hirotake Sakuraba |
| author_sort | Tetsuyuki Tateda |
| collection | DOAJ |
| description | <h4>Objective</h4> We evaluated the clinical characteristics of metabolic dysfunction-associated fatty liver disease (MAFLD) to evaluate the usefulness of the MAFLD diagnostic criteria in a resident health survey. <h4>Methods</h4> In 1056 participants of a health survey, we compared obesity, diabetes, metabolic dysregulation, FibroScan-aspartate aminotransferase (FAST) score, dietary habits, and gut microbiota between healthy individuals and participants with MAFLD and Nonalcoholic fatty liver disease (NAFLD). <h4>Results</h4> The proportion of participants with MAFLD in the fatty liver was higher than that with NAFLD (88.1% vs. 75.5%, respectively). Of 36 participants with a FAST score > 0.35, 29 (80.6%) participants had MAFLD and 23 (63.9%) participants had NAFLD. Of 29 patients with liver fibrosis, 26 (89.7%) participants had obesity and metabolic dysregulation. In the evaluation of diet, the total energy, protein, dietary fiber, and salt intake were significantly higher in participants with MAFLD than those in participants without fatty liver. In the microbiota analysis, the results of the linear discriminant analysis effect size analysis revealed nine bacterial genera that were significantly different in participants with MAFLD in comparison with participants without fatty liver. Of these genera, the relative abundance of Blautia was especially low in participants with MAFLD. <h4>Conclusion</h4> In a resident health survey, participants with MAFLD had a higher proportion of fatty liver than those with NAFLD. MAFLD criteria could help in improved screening of participants with liver fibrosis. Therefore, the MAFLD criteria could be a useful diagnostic tool for aggressively identifying participants with a high risk of fatty liver. Additionally, Blautia might be involved in the development of MAFLD. |
| first_indexed | 2024-04-11T15:45:40Z |
| format | Article |
| id | doaj.art-710c4f5fa8214f6b995b3cbdc872d2dd |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T15:45:40Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-710c4f5fa8214f6b995b3cbdc872d2dd2022-12-22T04:15:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011711Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional studyTetsuyuki TatedaChikara IinoTakafumi SasadaSatoshi SatoGo IgarashiShogo KawaguchiKenichiro MikamiTetsu EndoKaori SawadaTatsuya MikamiShinsaku FukudaShigeyuki NakajiHirotake Sakuraba<h4>Objective</h4> We evaluated the clinical characteristics of metabolic dysfunction-associated fatty liver disease (MAFLD) to evaluate the usefulness of the MAFLD diagnostic criteria in a resident health survey. <h4>Methods</h4> In 1056 participants of a health survey, we compared obesity, diabetes, metabolic dysregulation, FibroScan-aspartate aminotransferase (FAST) score, dietary habits, and gut microbiota between healthy individuals and participants with MAFLD and Nonalcoholic fatty liver disease (NAFLD). <h4>Results</h4> The proportion of participants with MAFLD in the fatty liver was higher than that with NAFLD (88.1% vs. 75.5%, respectively). Of 36 participants with a FAST score > 0.35, 29 (80.6%) participants had MAFLD and 23 (63.9%) participants had NAFLD. Of 29 patients with liver fibrosis, 26 (89.7%) participants had obesity and metabolic dysregulation. In the evaluation of diet, the total energy, protein, dietary fiber, and salt intake were significantly higher in participants with MAFLD than those in participants without fatty liver. In the microbiota analysis, the results of the linear discriminant analysis effect size analysis revealed nine bacterial genera that were significantly different in participants with MAFLD in comparison with participants without fatty liver. Of these genera, the relative abundance of Blautia was especially low in participants with MAFLD. <h4>Conclusion</h4> In a resident health survey, participants with MAFLD had a higher proportion of fatty liver than those with NAFLD. MAFLD criteria could help in improved screening of participants with liver fibrosis. Therefore, the MAFLD criteria could be a useful diagnostic tool for aggressively identifying participants with a high risk of fatty liver. Additionally, Blautia might be involved in the development of MAFLD.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683607/?tool=EBI |
| spellingShingle | Tetsuyuki Tateda Chikara Iino Takafumi Sasada Satoshi Sato Go Igarashi Shogo Kawaguchi Kenichiro Mikami Tetsu Endo Kaori Sawada Tatsuya Mikami Shinsaku Fukuda Shigeyuki Nakaji Hirotake Sakuraba Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study PLoS ONE |
| title | Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study |
| title_full | Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study |
| title_fullStr | Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study |
| title_full_unstemmed | Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study |
| title_short | Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study |
| title_sort | evaluation of metabolic dysfunction associated fatty liver disease using fibroscan diet and microbiota a large cross sectional study |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683607/?tool=EBI |
| work_keys_str_mv | AT tetsuyukitateda evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT chikaraiino evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT takafumisasada evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT satoshisato evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT goigarashi evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT shogokawaguchi evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT kenichiromikami evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT tetsuendo evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT kaorisawada evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT tatsuyamikami evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT shinsakufukuda evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT shigeyukinakaji evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy AT hirotakesakuraba evaluationofmetabolicdysfunctionassociatedfattyliverdiseaseusingfibroscandietandmicrobiotaalargecrosssectionalstudy |